Department Of Neurology 12
551. Dynamics of clinical and neurological changes in patients with acute ischemic stroke in an open clinical study
552. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023
553. Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021
554. Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021
555. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
556. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
557. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
558. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
559. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
560. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
561. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
562. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
563. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
564. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
565. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
566. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
567. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome
568. TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations
569. Autonomic dysfunction syndrome in pregnant women
570. Autonomic dysfunction syndrome in pregnant women
571. Retraction Note: Autonomic dysfunction syndrome in pregnant women (Acta Neurologica Belgica, (2021), 121, 6, (1429-1433), 10.1007/s13760-020-01312-7)
572. Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy
573. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
574. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
575. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
576. Epidemiology of Offences against Health in the Republic of Kazakhstan: 2015-2019
577. COVID-19-associated acute disseminated encephalomyelitis with Overlap syndrome in a teenager: A clinical case
578. The impact of Gam-COVID-Vac, an Adv5/ Adv26 COVID-19 vaccine, on the biomarkers of endothelial function, coagulation and platelet activation
579. REVEALING FINDINGS FROM A GENETIC STUDY OF CHILDREN AFFECTED BY DUCHENNE MYODYSTROPHY IN KAZAKHSTAN
580. The pantothenic acid derivative dexpanthenol ameliorated doxorubicin-induced neurotoxicity via regulating AKT/CREB/BDNF and AKT/NRF2 signaling pathways
581. ANALYSIS OF RISK FACTORS FOR ISCHEMIC STROKE IN RURAL RESIDENTS OF THE AKTOBE REGION
582. Bibliometric Analysis of the Role of Occludin in the Pathogenesis of Stroke
583. Bibliometric Analysis of Alpha-Synuclein Determination by Biopsy in Peripheral Tissues of Patients With Parkinson’s Disease
584. Optimized Electroencephalogram Preprocessing with Discrete Wavelet Transform and EfficientNet for High-Accuracy Seizure Detection
585. Apoptotic cell death in disease—Current understanding of the NCCD 2023
586. Development of a time-resolved immunochromatographic test strip for rapid and quantitative determination of GFAP in serum
587. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019
588. Global, regional, and national burden of suicide, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021
589. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
590. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
591. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
592. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
593. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
594. Diagnostic Algorithm Application in Pediatric Patients with Complex Neurological Phenotypes in South Kazakhstan
595. Integrating Genomics and Deep Phenotyping for Diagnosing Rare Pediatric Neurological Diseases: Potential for Sustainable Healthcare in Resource-Limited Settings
596. Uncovering Novel Anti-Lung Cancer Compounds: Insights from Marine Sponge-Derived Agents: A Bibliometric Review
597. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia
598. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia
599. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia
600. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia
1 10 11 12 13